increased solubility = different PK profile? [Dissolution / BCS / IVIVC]

posted by nobody – 2017-06-08 19:43 (2801 d 23:35 ago) – Posting: # 17467
Views: 14,888

❝ O.k., I see I need to add some more information. The idea behind this question is to develop an oral formulation with a less drug load than the reference product but with the same bioavailability in order to decrease non-systemic adverse events.


If you claim less AEs, you will have to proof it. In my opinion. So: Clinical trials ahead, I guess.

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,666 registered users;
230 visitors (0 registered, 230 guests [including 15 identified bots]).
Forum time: 18:19 CET (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5